What is the equity of Elan this year?
Elan has equity of 10.81 B JPY this year.
Elan Equity 2024
Elan Equity
10.81 B JPY
Ticker
6099.T
ISIN
JP3167680002
WKN
A12C13
In 2024, Elan's equity was 10.81 B JPY, a 20.3% increase from the 8.99 B JPY equity in the previous year.
Elan Aktienanalyse
What does Elan do?
Elan Corp is an Irish pharmaceutical company specializing in the research, development, and marketing of medications for neurological and autoimmune diseases. The company was founded in 1969 under the name Athlone Laboratories and has since undergone significant changes in both its business fields and its name. In 1996, the company was renamed Elan Corporation, a name it still holds today. At that time, the company primarily focused on researching and developing medications for Alzheimer's and Parkinson's diseases. However, in the following years, the company shifted its focus more towards treating autoimmune diseases such as multiple sclerosis and Crohn's disease. Elan Corp's business model is based on the development of medications through research and development as well as the acquisition of established therapeutics. One key component of the product portfolio is the medication Tysabri, which was developed in collaboration with Biogen Idec. It is used to treat multiple sclerosis patients and is one of Elan's top-selling medications, contributing significantly to the company's success. Elan Corp consists of three main business areas: 1. Biopharmaceuticals This division is responsible for the research and development of medications for neurological diseases such as Alzheimer's, Parkinson's, and multiple sclerosis. Some of the key products in this area, in addition to Tysabri, include Axona, a nutritional supplement to enhance cognitive function in Alzheimer's patients, and Zanaflex, which is used to treat muscle spasms in the majority of multiple sclerosis patients. 2. Neurology In this division, Elan focuses on the marketing and distribution of nerve and pain medications, as well as products for treating infections. Some of the key products in this area are Skelaxin, a muscle relaxant for pain and muscle spasms, and Biaxin, an antibiotic for treating infections. 3. Medical Technology Elan Corp's medical technology division specializes in the development and marketing of infusion pumps. The company primarily offers its products and services in the United States and Europe and holds a strong position in this market. Elan Corp is a company with a strong focus on research and development. Its key products are medications for treating neurological and autoimmune diseases, with Tysabri being the most well-known and successful. The company has undergone significant changes over the years and now focuses on developing medications for autoimmune diseases in the neurology field. With a strong emphasis on research and development, as well as the acquisition of established therapeutics, Elan Corp is an important player in the pharmaceutical industry and is expected to continue growing and succeeding in the future. Elan ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing Elan's Equity
Elan's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Elan's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating Elan's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
Elan's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in Elan’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about Elan stock
What was the equity of Elan compared to the previous year?
The equity of Elan has increased/decreased by 20.3% increased compared to the previous year.
What impact does a high equity have on investors of Elan?
A high equity is advantageous for investors of Elan as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of Elan?
A low equity can be a risk for investors of Elan, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of Elan affect the company?
An increase in equity of Elan can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of Elan affect the company?
A reduction in equity of Elan can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of Elan?
Some factors that can affect the equity of Elan include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of Elan so important for investors?
The equity of Elan is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can Elan take to change the equity?
To change equity, Elan can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does Elan pay?
Over the past 12 months, Elan paid a dividend of 13 JPY . This corresponds to a dividend yield of about 1.93 %. For the coming 12 months, Elan is expected to pay a dividend of 15.09 JPY.
What is the dividend yield of Elan?
The current dividend yield of Elan is 1.93 %.
When does Elan pay dividends?
Elan pays a quarterly dividend. This is distributed in the months of January, January, January, January.
How secure is the dividend of Elan?
Elan paid dividends every year for the past 13 years.
What is the dividend of Elan?
For the upcoming 12 months, dividends amounting to 15.09 JPY are expected. This corresponds to a dividend yield of 2.24 %.
In which sector is Elan located?
Elan is assigned to the 'Health' sector.
Wann musste ich die Aktien von Elan kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Elan from 3/1/2025 amounting to 14 JPY, you needed to have the stock in your portfolio before the ex-date on 12/27/2024.
When did Elan pay the last dividend?
The last dividend was paid out on 3/1/2025.
What was the dividend of Elan in the year 2023?
In the year 2023, Elan distributed 11 JPY as dividends.
In which currency does Elan pay out the dividend?
The dividends of Elan are distributed in JPY.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Elan
Our stock analysis for Elan Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Elan Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
